Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)
Stopped Lack of funding following full FDA clinical hold
Conditions
- Chronic Myelomonocytic Leukemia
- Juvenile Myelomonocytic Leukemia
- Atypical Chronic Myeloid Leukemia
- Myeloproliferative Neoplasm
- Myelodysplastic Syndromes
- Myelofibrosis
Interventions
- DRUG: Pacritinib
- DRUG: Decitabine
Sponsor
Washington University School of Medicine
Collaborators